Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pritchard, J.
Right arrow Articles by Hughes, R. A.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pritchard, J.
Right arrow Articles by Hughes, R. A.C.
Related Collections
Right arrow All Immunology
Right arrow Guillain-Barre syndrome
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2003;61:1282-1284
© 2003 American Academy of Neurology
Brief Communications

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome

J. Pritchard, BM BCh, I. A. Gray, MIScT, Z. R. Idrissova, PhD, B. R.F. Lecky, MD, I. J. Sutton, MB ChB, A. V. Swan, PhD, H. J. Willison, PhD, J. B. Winer, MD and R. A.C. Hughes, MD

From the Department of Clinical Neurosciences (J. Pritchard and I.A. Gray, and Drs. Idrissova, Swan, and Hughes), Guy’s, King’s & St. Thomas’ School of Medicine, London; The Walton Centre for Neurology and Neurosurgery (Dr. Lecky), Liverpool; the Department of Neurology (I.J. Sutton and Dr. Winer), Queen Elizabeth Hospital, Birmingham; and Institute of Neurological Sciences (Dr. Willison), Southern General Hospital, University of Glasgow, UK.

Address correspondence and reprint requests to Professor R.A.C. Hughes, Department of Clinical Neurosciences, Guy’s, King’s & St. Thomas’ School of Medicine, Hodgkin Building, Guy’s Hospital, London SE1 1UL, UK; e-mail: Richard.a.Hughes{at}kcl.ac.uk

The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFNß-1a) (Rebif). Participants received IFNß-1a or placebo subcutaneously three times weekly, 22 µg for the first week and then 44 µg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFNß did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.

Received May 20, 2003. Accepted in final form July 18, 2003.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281.
[Abstract] [PDF]

Home page
 BrainHome page
R. A. C. Hughes, A. V. Swan, J.-C. Raphael, D. Annane, R. van Koningsveld, and P. A. van Doorn
Immunotherapy for Guillain-Barre syndrome: a systematic review
Brain, September 1, 2007; 130(9): 2245 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung
Chronic Inflammatory Demyelinating Polyneuropathy
N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.